Beyaz is known as a fourth-generation birth control pill because it contains drospirenone, a synthetic version of progesterone. It is similar to Yasmin and Yaz - also fourth-generation birth control pills - but also has folate in its formulation. The issue with fourth-generation birth control pills - those containing drospirenone - is that some studies have linked them to an increased risk of blood clots.
Among those studies, the US Food and Drug Administration (FDA) reports, were studies that found as much as three times the risk of blood clots in drosperinone-containing birth control compared with other birth control and some studies that found no increased risk.
That increased risk is still relatively small. Women who are pregnant are also at an increased risk of blood clots, the FDA notes. But the issue is not only one of the actual risks and benefits to Beyaz itself, it’s that there are older birth control pills that are reportedly as effective as Beyaz but do not come with the same risk of blood clots. Meanwhile, a study funded by the FDA also found an increased risk of blood clots associated with fourth-generation birth control pills.
So why would the FDA leave fourth-generation birth control pills on the market, when there are safer drugs that are just as effective?
READ MORE BEYAZ LEGAL NEWS
The panel did vote that the warning label at the time did not adequately warn about the risks, and the FDA updated the label for the drugs, noting that some studies indicated an increased risk of blood clots associated with drospirenone-containing birth control.